Drug Pricing & Access
Expert articles and analysis related to drug pricing & access.
AI Summary â Last 7 Days
Drug pricing and access policy is shifting from broad affordability rhetoric into operational payment changes: CMSâ 2027 OPPS proposal would pair a 2.4% update with steep 340B reductions and lower hospital payments for certain drugs and imaging services, intensifying site-neutral and drug-margin pressure for hospital-based ACO participants and safety-net systems (HealthLeaders). At the same time, Congress is advancing bipartisan drug pricing, PBM oversight, Medicare Advantage, and hospital price transparency bills, while CMS is also withholding Medicaid funds from California and Minnesota over alleged in-home care fraud.
Related Articles
Drug pricing and the IRA: Tracking the government's negotiation power
Drug pricing and the IRA: Tracking the government's negotiation power  Endpoints News
The Drug Changing Medicine
By EMANUEL SARKEES The United States is in the middle of what researchers are calling one of the most significant pharmacological developments in modern medicine. GLP-1 receptor agonists, the drug cla...
Medicaid MFN Pricing Could Save $8.6 Billion
A Prescription for Drug Costs: Inject Transparency and Improve Accessibility
A Prescription for Drug Costs: Inject Transparency and Improve Accessibility  MedCity News
Whatâs Next For Prescription Drug Affordability Boards After Amgen v. Mizner?
Whatâs Next For Prescription Drug Affordability Boards After Amgen v. Mizner?  Health Affairs
Legislation Advances to Lower Drug Costs and Enhance Federal Oversight
Legislation Advances to Lower Drug Costs and Enhance Federal Oversight  HCI Innovation Group
Court rules that companies may not impose 340B rebate model without HHS approval
Court rules that companies may not impose 340B rebate model without HHS approval  American Hospital Association
STAT+: Rare disease drugmakers try to avoid Trump price cuts
Plus, GOP voters want a crackdown on health care fraud, and how PBMs are skirting state laws.